AND EXCHANGE COMMISSION
to Section 13 or 15(d) of the Securities Exchange Act of 1934
of Report (Date of earliest event reported): August 14, 2017
Biomedical Holdings, Inc.
name of registrant as specified in its charter)
|(State or Other Jurisdiction
CambridgePark Drive, Suite 2000
of Principal Executive Offices)
telephone number, including area code)
name or former address, if changed since last report)
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Results of Operations and Financial Condition.
August 14, 2017, Enumeral Biomedical Holdings, Inc. issued a press release announcing its financial results for the three
month period ended June 30, 2017. The press release is attached to this report as Exhibit 99.1.
information in this Form 8-K and Exhibit 99.1 is not deemed “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor is it deemed incorporated by reference
in any filing under the Securities Act of 1933 or Securities Exchange Act of 1934, except as specifically indicated in any such
information contained in Item 2.02 above is incorporated herein by reference.
Financial Statements and Exhibits.
Release dated August 14, 2017.|
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
||ENUMERAL BIOMEDICAL HOLDINGS,
|Dated: August 14, 2017
Kevin G. Sarney|
||Kevin G. Sarney|
||Interim Chief Executive Officer and President,
Vice President of Finance, Chief Accounting Officer and Treasurer|